CRISPR gets a mention in the latest IPCC report as a potentially useful tool to cope with climate change. However, some people believe that biotech crops are safe and that climate change is not real (let’s call them libertarian capitalists, for convenience). Many ecological activists conversely think that genetically modified plants are evil and global warming threatens life on the planet. These stances could not be more different, yet they have something in common: they are both half right and half wrong. They are both examples of “selective science denial.” Continue reading
We talk of cryptic mutations when genes are changed in a way that remains hidden until they interact with other mutations. As a result, combining beneficial traits can have negative consequences hindering agricultural production (watch this video from Cold Spring Harbor Laboratory on unexpected negative interactions). Classic breeders have been dealing with this problem for decades, but researchers from CSHL are finally working on a solution suitable for the genomic era. Zach Lippman and colleagues have studied one infamous cryptic mutation affecting a tomato variety developed by the Campbell Soup Company in the 1960s and discuss an anti-negative-interaction strategy for the future. Please see their paper in Nature Plants and watch the video below offering a cautionary tale for crop gene editing.
The best TED talks about gene editing, selected by The Bench blog
Researchers from Penn Medicine and Children’s Hospital of Philadelphia have fixed a lethal mutation in the prenatal mouse models of a rare pulmonary disease. The hope is that the approach of in utero editing described in Science Translational Medicine will work for other congenital lung diseases as well.
I asked one of the corresponding authors, Edward Morrison, scientific director of the Penn’s Institute for Regenerative Medicine, to explain what they have done and what to expect next. See Q&A below. Continue reading
If you know the enemy and know yourself, you need not fear the result of a hundred battles. The military strategist Sun Tzu wrote it over two thousand years ago, but this quote could also apply to oncology research in the CRISPR era. Identifying the weak points of cancer cells is the first step to hit new molecular targets with the next generation of drugs.
The good news is that the Wellcome Sanger Institute has taken a giant leap toward this goal, drawing up a list of 600 candidate genes. The study just published in Nature by Mathew Garnett’s team comes with a twin paper by the Broad Institute, confirming the results by following an alternative approach. In a four-year tour de force of functional genomics, Sanger’s researchers used CRISPR to disrupt every gene in over 300 cancer models from 30 cancer types. From this amount of data, they developed a prioritization system which will guide big pharma’s hunt for new drugs.
“Wow! Badass. 13,200 crispr base edits in a single cell! On the way to ‘recoded’ human cells,” tweeted Antonio Regalado before covering the news in MIT Technology Review. To be honest, the radical redesign of species is still sci-fi dystopia, but the paper preprinted by Cory J. Smith et al. in bioRxiv is impressive anyway. Continue reading